Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer

SIMPLE SUMMARY: Therapies with monoclonal antibodies (mAbs) targeting tumor-associated antigens (TAAs) or immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. Nevertheless, the inevitable development of resistance and the failure to respond are among this approach’s disadvantage...

Descripción completa

Detalles Bibliográficos
Autores principales: Tobias, Joshua, Drinić, Mirjana, Schmid, Anna, Hladik, Anastasiya, Watzenböck, Martin L., Battin, Claire, Garner-Spitzer, Erika, Steinberger, Peter, Kundi, Michael, Knapp, Sylvia, Zielinski, Christoph C., Wiedermann, Ursula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688220/
https://www.ncbi.nlm.nih.gov/pubmed/36428769
http://dx.doi.org/10.3390/cancers14225678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688220/
https://www.ncbi.nlm.nih.gov/pubmed/36428769
http://dx.doi.org/10.3390/cancers14225678

Ejemplares similares